What is the response rate of adagrasib (Krazati) treatment and analysis of its impact on survival

Adagrasib (trade name: Krazati) is an oral KRAS G12C inhibitor developed by Merck. It is mainly used to treat patients with KRAS G12C mutation-positive advanced non-small cell lung cancer (NSCLC). As a precise targeted drug, it can directly act on the KRAS mutant protein, thereby inhibiting tumor cell proliferation. It is an important breakthrough in the treatment of KRAS mutation-driven tumors.

Clinical studies have shown that adagrasib has significant efficacy in patients with previously treated KRAS G12C mutated NSCLC. Research data shows that its objective response rate (ORR) is about 43%, and its disease control rate (DCR) can reach about 80%. This means that nearly half of patients can achieve significant tumor shrinkage or stable disease, thereby improving their quality of life.

In terms of survival, adagrasib showed potential to extend progression-free survival (PFS). The median progression-free survival is approximately 6 to 7 months, and the median overall survival (OS) still shows a longer trend during follow-up. For patients who have failed prior chemotherapy or immunotherapy, adagrasib offers new treatment opportunities that can help slow disease progression and improve overall prognosis.
Overall, adagrasib, as a KRAS G12C inhibitor, has demonstrated good objective response rates and disease control capabilities, and has a positive impact on patients' progression-free survival and overall survival. It provides a new precision treatment option for patients with KRAS mutation-positive advanced lung cancer, and also promotes the development of KRAS-targeted drugs in clinical applications. In the future, as more studies and real-world data accumulate, its potential for survival benefit and combination treatment strategies will be further clarified.
Reference link: https://www.drugs.com